Low libido and erectile dysfunction need separate assessment. See where morning erections, medical history and testosterone testing fit.
Low libido concerns sexual interest, while erectile dysfunction concerns erection firmness and duration, a distinction that shapes how clinicians assess sexual symptoms and possible testosterone deficiency.
This article is for informational purposes only and is not medical advice. Individual evaluation and treatment decisions belong with a qualified clinician.
Low libido means reduced interest in sex. It describes desire, rather than the ability to get or keep an erection. A man may have less sexual interest without reporting erection difficulty, just as erection difficulty may occur while sexual interest remains intact.
The European Association of Urology (EAU) treats desire as one part of a sexual history. It recommends asking separately about arousal and erection quality. Ejaculation, orgasm and sexual satisfaction are also distinct parts of that discussion.
This is useful because a general description of poorer sexual function leaves several questions unanswered. Less interest in sex is different from interest that remains present but is accompanied by an erection problem. A clinical assessment needs to establish which aspect has changed.
Separating the reported changes helps establish whether the concern involves desire, erection function or both. Describing sexual interest separately helps the clinician avoid using erection performance as a stand-in for libido. The aim is to give the concern a clear name before considering possible explanations.
For more background on that distinction, Testostra explains how sexual symptoms fit into a testosterone assessment. The focus is on connecting a reported change with an appropriate clinical evaluation, rather than assigning a cause from a symptom label.
The EAU defines erectile dysfunction as persistent difficulty attaining or maintaining an erection sufficient for satisfactory sexual performance. This makes persistence and erection function central to the definition. ED is not simply another term for reduced sexual interest.
The functional difference is straightforward: desire describes interest in sexual activity, while erection function describes attaining and maintaining the erection itself. Clinicians ask about both firmness and duration. Those details are more specific than a single report that sexual performance has changed.
The EAU classifies ED as organic, psychogenic or mixed. In plain language, physical causes or psychological causes may be involved together. The guideline describes vascular and hormonal contributors alongside neurologic and psychological ones.
The associated conditions and risk factors extend beyond hormone disorders. The EAU lists diabetes and cardiovascular disease. It also includes obesity and smoking, along with depression, anxiety and sleep disorders.
These categories are not competing explanations that require the clinician to choose only one. The guideline notes that many cases have mixed causes. The clinical task is therefore to assess possible contributors together rather than assume that the first relevant finding explains the whole problem.
Medication history also matters. The EAU lists some antihypertensives, antidepressants, antipsychotics and antiandrogens among possible medication-related contributors. It also notes that cardiovascular medicines may have detrimental or neutral effects, while others may have beneficial effects on erectile function.
That detail makes the exact medication list more informative than a broad label such as heart medicine. Reviewing medicines belongs within the clinical assessment. The guideline does not treat every cardiovascular drug as having the same effect.
Cardiovascular health is another reason to assess ED broadly. The EAU says ED should prompt assessment of cardiovascular risk and disease. Testostra’s discussion of why erection concerns lead beyond hormone testing gives further context for this part of the evaluation.
The overlap between desire and erections matters because sexual symptoms are relevant to the assessment of testosterone deficiency. The EAU describes sexual symptoms as the most specific symptoms associated with late-onset hypogonadism. Clinicians weigh those symptoms within a wider medical and laboratory assessment.
The question is not simply whether desire or erections are more important. It is how each reported change fits with the man’s health history and hormone results. The EAU’s separate questions about desire and erection quality give clinicians a way to preserve those distinctions.
Morning erections add another part of the history. The EAU recommends recording their rigidity and duration separately from erections during sexual activity. A description of morning erections therefore belongs alongside the account of desire and erections in other settings.
The useful distinction is between three observations: sexual interest, erection firmness and duration during sexual activity, and morning erection firmness and duration. Keeping those observations separate makes the account more precise. Morning erections are an additional part of the sexual history rather than a replacement for the other questions.
EAU guidance recommends a comprehensive medical and sexual history for men presenting with ED. It also recommends a focused physical examination and relevant laboratory testing. This framework places the symptom within the man’s wider health rather than limiting the discussion to testosterone.
Psychological and relationship context are part of that assessment. The guideline recommends asking about life stressors and thought patterns, as well as partner-related or performance-related concerns. Relationship factors belong in the history too.
These questions are part of a broad clinical assessment, not an alternative to taking the physical complaint seriously. They help preserve both sides of the history: the reported difficulty and the circumstances surrounding it. The purpose is to understand the concern fully before drawing a clinical conclusion.
The laboratory assessment described by the EAU can include glucose and lipids alongside total testosterone. These tests address different parts of the wider evaluation. A visit focused on erections may therefore involve questions and tests that extend beyond reproductive hormones.
For testosterone assessment in ED, the EAU specifies an early-morning fasting total testosterone measurement. Its male-hypogonadism guidance requires compatible symptoms or signs together with consistently low morning total testosterone on at least two occasions. Measurements should use a reliable assay and be taken in fasting conditions.
This is the key diagnostic limit: neither one sexual symptom nor a single testosterone result establishes testosterone deficiency. The symptom distinctions also do not identify the cause in an individual man. They help organize the assessment needed to interpret both the complaint and the laboratory evidence.
That is why the discussion includes how a result fits the symptoms and whether biochemical findings have been confirmed. Testostra’s guide to putting hormone measurements into clinical context develops this distinction between a laboratory result and a clinical conclusion.
The EAU’s approach supports a description that separates the main aspects of sexual function instead of grouping everything under low testosterone. Useful details for a clinical conversation include:
These descriptions are a way to communicate observations rather than carry out a home diagnostic test. The clinician then connects the history with examination findings and relevant tests. This keeps both sexual function and possible testosterone deficiency within a proper clinical evaluation.
Desire, erection quality and morning erections form one clinical picture, best understood alongside medical history and appropriately confirmed testosterone results.
Sexual symptoms put the treating clinician in charge of the medical assessment; Testostra’s part is clear reporting on testosterone evidence. Its coverage of testing and biomarkers gives readers context for total testosterone, free testosterone and SHBG, while keeping general education separate from personal diagnosis and treatment.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra